Today’s pharmaceutical and medical device companies are facing rising pressure from healthcare communities with patients needing more personalized care, consumers and policy makers pushing to lower healthcare costs, the drive to reduce time and costs to bring new products to market, and complying with increasingly onerous regulations. Meanwhile, the industry is focused on developing more innovative products that improve patient outcomes while decreasing healthcare costs. How does a pharmaceutical or medical device company even begin to try and achieve all these objectives?
Innovating while simultaneously reducing the time and cost of bringing products to market are critical to the financial stability and growth of life science companies. And achieving these goals, without sacrificing quality and patient safety is a prerequisite that is extremely hard to satisfy. Today, in silico (computer-based) methods allow multidisciplinary design teams to perform a large number of simulations to test a variety of designs and therapeutics under various conditions prior to costly and time-consuming physical prototype builds and lab testing that would otherwise not be possible with animal studies and human clinical trials.
Join us for our webinar as we demonstrate the power of modeling and simulation for pharma and medical device companies, and why it’s so important in today’s Life Sciences industry.
Karl D’Souza, Life Sciences Industry Solution Experience Director, Dassault Systèmes
Karl D’Souza is a computational modeling and simulation professional with extensive experience in technology consulting, product management, and business development as they pertain to simulation-based solutions for science and technology companies. In his current role as Life Sciences Industry Solution Experience Director at Dassault Systemes, he is responsible for managing the Design and Engineering portfolio of Dassault Systemes’ solutions for medical devices, bio-pharmaceuticals, and patient care. Prior to his current role, he helped grow Dassault Systemes’ Virtual Human Modeling initiative with special focus on cardiovascular and neurological applications, and was a founding member of the Living Heart Project and product manager of the Living Heart Human Model. Karl has a B. Tech in Materials Science and Engineering from IIT Bombay, a MS in Mechanical Engineering from SUNY Buffalo, and an MBA from Bryant University, and is based in Providence, RI, USA. Feel free to reach out to Karl by sending him an email at email@example.com.Message Presenter
Who Should Attend?
This webinar will be of interest to those in the biopharmaceutical and medical device industries, with relevant job areas including:
- Quality Assurance
- Product Manufacturing
- R&D Technical Staff
- Clinical Researchers
What You Will Learn
Join this webinar where our featured speaker will show how in-silico methods can:
- Reduce reliance on animal models and human clinical trial data
- Accelerate innovation
- Improve quality design and patient safety
- Expedite time to market
- Lower development and clinical trial costs
Dassault Systèmes, the 3DEXPERIENCE COMPANY, provides business and people with virtual universes to imagine sustainable innovations. The Dassault Systèmes 3DEXPERIENCE® platform solutions provide medical device manufacturers with the ability to effectively and efficiently manage quality issues by improving traceability and QSR/GMP/ISO compliance while eliminating non-value-added activities. This can help companies avoid compliance risk, reduce waste and deliver unmatched quality, safety and efficacy.